Report cover image

Global Recombinant Vector Vaccines Market by Size, by Type, by Application, by Region, History and Forecast 2020-2031

Publisher APO Research, Inc.
Published Oct 20, 2025
Length 191 Pages
SKU # APRC20552861

Description

Summary

According to APO Research, The global Recombinant Vector Vaccines market is projected to grow from US$ million in 2025 to US$ million by 2031, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The US & Canada market for Recombinant Vector Vaccines is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Asia-Pacific market for Recombinant Vector Vaccines is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The China market for Recombinant Vector Vaccines is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Europe market for Recombinant Vector Vaccines is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The major global manufacturers of Recombinant Vector Vaccines include SANOFI PASTEUR S.A., CNBG, SINOVAC BIOTECH, Zhifei, GSK, Hualan Bio, ChengDa Bio, NuoCheng Bio and Novartis, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Recombinant Vector Vaccines, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2020-2024, estimates for 2025, and projections of CAGR through 2031.

This report researches the key producers of Recombinant Vector Vaccines, also provides the sales of main regions and countries. Of the upcoming market potential for Recombinant Vector Vaccines, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Recombinant Vector Vaccines sales, revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global Recombinant Vector Vaccines market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2020 to 2031. Evaluation and forecast the market size for Recombinant Vector Vaccines sales, projected growth trends, production technology, application and end-user industry.


Recombinant Vector Vaccines Segment by Company


SANOFI PASTEUR S.A.
CNBG
SINOVAC BIOTECH
Zhifei
GSK
Hualan Bio
ChengDa Bio
NuoCheng Bio
Novartis
Kangtai
Changsheng Life

Recombinant Vector Vaccines Segment by Type


Varicella
Influenza
Hepatitis
Pneumococcal
Pertussis, Diphtheria, tetanus
Others

Recombinant Vector Vaccines Segment by Application


For Adult
For Child

Recombinant Vector Vaccines Segment by Region


North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Recombinant Vector Vaccines market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Recombinant Vector Vaccines and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Recombinant Vector Vaccines.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Recombinant Vector Vaccines market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2020-2031).
Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Recombinant Vector Vaccines manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Recombinant Vector Vaccines in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Revenue of Recombinant Vector Vaccines in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights of the report

Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.

Table of Contents

191 Pages
1 Market Overview
1.1 Product Definition
1.2 Global Recombinant Vector Vaccines Market Size, 2020 VS 2024 VS 2031
1.3 Global Recombinant Vector Vaccines Market Size Estimates and Forecasts (2020-2031)
1.4 Global Recombinant Vector Vaccines Sales Estimates and Forecasts (2020-2031)
1.5 Global Recombinant Vector Vaccines Market Average Price (2020-2031)
1.6 Assumptions and Limitations
1.7 Study Goals and Objectives
2 Global Recombinant Vector Vaccines Market Dynamics
2.1 Recombinant Vector Vaccines Industry Trends
2.2 Recombinant Vector Vaccines Industry Drivers
2.3 Recombinant Vector Vaccines Industry Opportunities and Challenges
2.4 Recombinant Vector Vaccines Industry Restraints
3 Recombinant Vector Vaccines Market by Manufacturers
3.1 Global Recombinant Vector Vaccines Revenue by Manufacturers (2020-2025)
3.2 Global Recombinant Vector Vaccines Sales by Manufacturers (2020-2025)
3.3 Global Recombinant Vector Vaccines Average Sales Price by Manufacturers (2020-2025)
3.4 Global Recombinant Vector Vaccines Industry Manufacturers Ranking, 2023 VS 2024 VS 2025
3.5 Global Recombinant Vector Vaccines Key Manufacturers Manufacturing Sites & Headquarters
3.6 Global Recombinant Vector Vaccines Manufacturers, Product Type & Application
3.7 Global Recombinant Vector Vaccines Manufacturers Establishment Date
3.8 Market Competitive Analysis
3.8.1 Global Recombinant Vector Vaccines Market CR5 and HHI
3.8.2 Global Top 5 and 10 Recombinant Vector Vaccines Players Market Share by Revenue in 2024
3.8.3 2024 Recombinant Vector Vaccines Tier 1, Tier 2, and Tier 3
4 Recombinant Vector Vaccines Market by Type
4.1 Recombinant Vector Vaccines Type Introduction
4.1.1 Varicella
4.1.2 Influenza
4.1.3 Hepatitis
4.1.4 Pneumococcal
4.1.5 Pertussis, Diphtheria, tetanus
4.1.6 Others
4.2 Global Recombinant Vector Vaccines Sales by Type
4.2.1 Global Recombinant Vector Vaccines Sales by Type (2020 VS 2024 VS 2031)
4.2.2 Global Recombinant Vector Vaccines Sales by Type (2020-2031)
4.2.3 Global Recombinant Vector Vaccines Sales Market Share by Type (2020-2031)
4.3 Global Recombinant Vector Vaccines Revenue by Type
4.3.1 Global Recombinant Vector Vaccines Revenue by Type (2020 VS 2024 VS 2031)
4.3.2 Global Recombinant Vector Vaccines Revenue by Type (2020-2031)
4.3.3 Global Recombinant Vector Vaccines Revenue Market Share by Type (2020-2031)
5 Recombinant Vector Vaccines Market by Application
5.1 Recombinant Vector Vaccines Application Introduction
5.1.1 For Adult
5.1.2 For Child
5.2 Global Recombinant Vector Vaccines Sales by Application
5.2.1 Global Recombinant Vector Vaccines Sales by Application (2020 VS 2024 VS 2031)
5.2.2 Global Recombinant Vector Vaccines Sales by Application (2020-2031)
5.2.3 Global Recombinant Vector Vaccines Sales Market Share by Application (2020-2031)
5.3 Global Recombinant Vector Vaccines Revenue by Application
5.3.1 Global Recombinant Vector Vaccines Revenue by Application (2020 VS 2024 VS 2031)
5.3.2 Global Recombinant Vector Vaccines Revenue by Application (2020-2031)
5.3.3 Global Recombinant Vector Vaccines Revenue Market Share by Application (2020-2031)
6 Global Recombinant Vector Vaccines Sales by Region
6.1 Global Recombinant Vector Vaccines Sales by Region: 2020 VS 2024 VS 2031
6.2 Global Recombinant Vector Vaccines Sales by Region (2020-2031)
6.2.1 Global Recombinant Vector Vaccines Sales by Region (2020-2025)
6.2.2 Global Recombinant Vector Vaccines Sales Forecasted by Region (2025-2030)
6.3 North America
6.3.1 North America Recombinant Vector Vaccines Sales Growth Rate by Country: 2020 VS 2024 VS 2031
6.3.2 North America Recombinant Vector Vaccines Sales by Country (2020-2031)
6.3.3 U.S.
6.3.4 Canada
6.3.5 Mexico
6.4 Europe
6.4.1 Europe Recombinant Vector Vaccines Sales Growth Rate by Country: 2020 VS 2024 VS 2031
6.4.2 Europe Recombinant Vector Vaccines Sales by Country (2020-2031)
6.4.3 Germany
6.4.4 France
6.4.5 U.K.
6.4.6 Italy
6.4.7 Netherlands
6.5 Asia Pacific
6.5.1 Asia Pacific Recombinant Vector Vaccines Sales Growth Rate by Country: 2020 VS 2024 VS 2031
6.5.2 Asia Pacific Recombinant Vector Vaccines Sales by Country (2020-2031)
6.5.3 China
6.5.4 Japan
6.5.5 South Korea
6.5.6 Southeast Asia
6.5.7 India
6.5.8 Australia
6.6 South America, Middle East and Africa
6.6.1 South America, Middle East and Africa Recombinant Vector Vaccines Sales Growth Rate by Country: 2020 VS 2024 VS 2031
6.6.2 South America, Middle East and Africa Recombinant Vector Vaccines Sales by Country (2020-2031)
6.6.3 Brazil
6.6.4 South Africa
6.6.5 Saudi Arabia
6.6.6 Turkey
6.6.6 Argentina
6.6.6 UAE
6.6.6 Egypt
6.6.6 Chile
7 Global Recombinant Vector Vaccines Revenue by Region
7.1 Global Recombinant Vector Vaccines Revenue by Region
7.1.1 Global Recombinant Vector Vaccines Revenue by Region: 2020 VS 2024 VS 2031
7.1.2 Global Recombinant Vector Vaccines Revenue by Region (2020-2025)
7.1.3 Global Recombinant Vector Vaccines Revenue by Region (2026-2031)
7.1.4 Global Recombinant Vector Vaccines Revenue Market Share by Region (2020-2031)
7.2 North America
7.2.1 North America Recombinant Vector Vaccines Revenue (2020-2031)
7.2.2 North America Recombinant Vector Vaccines Revenue Share by Country: 2020 VS 2024 VS 2031
7.3 Europe
7.3.1 Europe Recombinant Vector Vaccines Revenue (2020-2031)
7.3.2 Europe Recombinant Vector Vaccines Revenue Share by Country: 2020 VS 2024 VS 2031
7.4 Asia-Pacific
7.4.1 Asia-Pacific Recombinant Vector Vaccines Revenue (2020-2031)
7.4.2 Asia-Pacific Recombinant Vector Vaccines Revenue Share by Country: 2020 VS 2024 VS 2031
7.5 South America, Middle East and Africa
7.5.1 South America, Middle East and Africa Recombinant Vector Vaccines Revenue (2020-2031)
7.5.2 South America, Middle East and Africa Recombinant Vector Vaccines Revenue Share by Country: 2020 VS 2024 VS 2031
8 Company Profiles
8.1 SANOFI PASTEUR S.A.
8.1.1 SANOFI PASTEUR S.A. Comapny Information
8.1.2 SANOFI PASTEUR S.A. Business Overview
8.1.3 SANOFI PASTEUR S.A. Recombinant Vector Vaccines Sales, Price, Revenue and Gross Margin (2020-2025)
8.1.4 SANOFI PASTEUR S.A. Recombinant Vector Vaccines Product Portfolio
8.1.5 SANOFI PASTEUR S.A. Recent Developments
8.2 CNBG
8.2.1 CNBG Comapny Information
8.2.2 CNBG Business Overview
8.2.3 CNBG Recombinant Vector Vaccines Sales, Price, Revenue and Gross Margin (2020-2025)
8.2.4 CNBG Recombinant Vector Vaccines Product Portfolio
8.2.5 CNBG Recent Developments
8.3 SINOVAC BIOTECH
8.3.1 SINOVAC BIOTECH Comapny Information
8.3.2 SINOVAC BIOTECH Business Overview
8.3.3 SINOVAC BIOTECH Recombinant Vector Vaccines Sales, Price, Revenue and Gross Margin (2020-2025)
8.3.4 SINOVAC BIOTECH Recombinant Vector Vaccines Product Portfolio
8.3.5 SINOVAC BIOTECH Recent Developments
8.4 Zhifei
8.4.1 Zhifei Comapny Information
8.4.2 Zhifei Business Overview
8.4.3 Zhifei Recombinant Vector Vaccines Sales, Price, Revenue and Gross Margin (2020-2025)
8.4.4 Zhifei Recombinant Vector Vaccines Product Portfolio
8.4.5 Zhifei Recent Developments
8.5 GSK
8.5.1 GSK Comapny Information
8.5.2 GSK Business Overview
8.5.3 GSK Recombinant Vector Vaccines Sales, Price, Revenue and Gross Margin (2020-2025)
8.5.4 GSK Recombinant Vector Vaccines Product Portfolio
8.5.5 GSK Recent Developments
8.6 Hualan Bio
8.6.1 Hualan Bio Comapny Information
8.6.2 Hualan Bio Business Overview
8.6.3 Hualan Bio Recombinant Vector Vaccines Sales, Price, Revenue and Gross Margin (2020-2025)
8.6.4 Hualan Bio Recombinant Vector Vaccines Product Portfolio
8.6.5 Hualan Bio Recent Developments
8.7 ChengDa Bio
8.7.1 ChengDa Bio Comapny Information
8.7.2 ChengDa Bio Business Overview
8.7.3 ChengDa Bio Recombinant Vector Vaccines Sales, Price, Revenue and Gross Margin (2020-2025)
8.7.4 ChengDa Bio Recombinant Vector Vaccines Product Portfolio
8.7.5 ChengDa Bio Recent Developments
8.8 NuoCheng Bio
8.8.1 NuoCheng Bio Comapny Information
8.8.2 NuoCheng Bio Business Overview
8.8.3 NuoCheng Bio Recombinant Vector Vaccines Sales, Price, Revenue and Gross Margin (2020-2025)
8.8.4 NuoCheng Bio Recombinant Vector Vaccines Product Portfolio
8.8.5 NuoCheng Bio Recent Developments
8.9 Novartis
8.9.1 Novartis Comapny Information
8.9.2 Novartis Business Overview
8.9.3 Novartis Recombinant Vector Vaccines Sales, Price, Revenue and Gross Margin (2020-2025)
8.9.4 Novartis Recombinant Vector Vaccines Product Portfolio
8.9.5 Novartis Recent Developments
8.10 Kangtai
8.10.1 Kangtai Comapny Information
8.10.2 Kangtai Business Overview
8.10.3 Kangtai Recombinant Vector Vaccines Sales, Price, Revenue and Gross Margin (2020-2025)
8.10.4 Kangtai Recombinant Vector Vaccines Product Portfolio
8.10.5 Kangtai Recent Developments
8.11 Changsheng Life
8.11.1 Changsheng Life Comapny Information
8.11.2 Changsheng Life Business Overview
8.11.3 Changsheng Life Recombinant Vector Vaccines Sales, Price, Revenue and Gross Margin (2020-2025)
8.11.4 Changsheng Life Recombinant Vector Vaccines Product Portfolio
8.11.5 Changsheng Life Recent Developments
9 Value Chain and Sales Channels Analysis
9.1 Recombinant Vector Vaccines Value Chain Analysis
9.1.1 Recombinant Vector Vaccines Key Raw Materials
9.1.2 Raw Materials Key Suppliers
9.1.3 Manufacturing Cost Structure
9.1.4 Recombinant Vector Vaccines Production Mode & Process
9.2 Recombinant Vector Vaccines Sales Channels Analysis
9.2.1 Direct Comparison with Distribution Share
9.2.2 Recombinant Vector Vaccines Distributors
9.2.3 Recombinant Vector Vaccines Customers
10 Concluding Insights
11 Appendix
11.1 Reasons for Doing This Study
11.2 Research Methodology
11.3 Research Process
11.4 Authors List of This Report
11.5 Data Source
11.5.1 Secondary Sources
11.5.2 Primary Sources
11.6 Disclaimer
How Do Licenses Work?
Request A Sample
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.